Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 13, 2018

Fresenius Medical Care to market Humacyte’s bioengineered blood vessel

German dialysis products company Fresenius Medical Care has entered a strategic global partnership with US-based medical research firm Humacyte over the investigational human acellular vessel Humacyl.

German dialysis products company Fresenius Medical Care has entered a strategic global partnership with US-based medical research firm Humacyte over the investigational human acellular vessel Humacyl.

Under the agreement, Fresenius Medical Care will gain exclusive global rights to commercialise the haemodialysis product designed for patients with end-stage renal disease (ESRD).

The company will be able to market, sell and distribute the product following approval from health authorities.

As part of the deal, Fresenius Medical Care will also make an equity investment of $150m, which will fetch the company a 19% fully diluted ownership stake in Humacyte.

“Under the agreement, Fresenius Medical Care will gain exclusive global rights to commercialise the haemodialysis product designed for patients with end-stage renal disease (ESRD).”

The move is expected to provide global ESRD patients with access to Humacyte’s bioengineered human acellular vessels, after approval of the product.

Subject to customary closing conditions, the transaction is expected to be completed next month.

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

Fresenius Medical Care North America chief medical officer Franklin Maddux said: “Our exclusive rights to distribute this innovative technology to dialysis patients worldwide may have significant benefits not only to patients but health systems as well.

“With the potential for fewer anticipated complications and interventions compared to synthetic grafts, we may see increased safety for patients and reduced medical and economic burdens to the healthcare system.”

Currently, Humacyte is evaluating its product in Phase III clinical trials in the US and Europe for vascular access during haemodialysis and expects Humacyl to be more effective than existing synthetic grafts and fistula.

Humacyte CEO and chairman Carrie Cox said: “Our partnership will allow Humacyte to focus on advancing the potential for Humacyl as a substantial breakthrough in the science of regenerative medicine, and to continue our development of an exciting future pipeline.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU